查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703422

基因治療市場－全球產業規模、佔有率、趨勢、機會及預測（依載體類型、遞送方式、適應症、地區及競爭情況分類，2020-2030 年預測）

Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vector Type, By Delivery Method, By Indication, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球基因治療市場價值為 65.4 億美元，預計到 2030 年將達到 112.9 億美元，預測期內複合年成長率為 9.53%。基因療法被描述為透過改變、替換或補充導致疾病的缺失或缺陷的基因組合來治療疾病。基因治療已成為對抗退化性疾病最令人嚮往的研究目標之一。全球範圍內癌症和其他慢性疾病病例數量的增加推動了對基因治療的需求。基因治療的進步預計將在未來幾年獲得批准，從而促進預測期內基因治療市場的成長。基因療法旨在透過改變遺傳訊息來治療疾病，例如使功能失調的基因失去活性或用健康的基因副本替換致病基因。基因療法已被用於治療多種疾病，並已被證明是有效的。這種治療方法可以治療糖尿病、癌症、心臟病和愛滋病等疾病。

市場概覽
預測期 2026-2030
2024年市場規模 65.4億美元
2030年市場規模 112.9億美元
2025-2030 年複合年成長率 9.53%
成長最快的領域 非病毒載體
最大的市場 北美洲

預計強大的基因治療產品線將在預測期內推動市場成長。研究人員正在積極致力於使基因療法在臨床環境中更容易獲得。許多大學和研究機構正在開發各種各樣的基因療法產品，預計這些產品將在未來幾年為創造收入做出重大貢獻。自 FDA 批准首個基因療法以來，2017 年至 2018 年間，基因療法臨床試驗的數量顯著增加。根據美國基因與細胞治療學會（ASGCT）統計，目前約有1986種基因治療產品正在開發中，包括CAR-T細胞療法和其他基因改造細胞療法，進一步加速了市場擴張。

關鍵市場促進因素

遺傳學研究的進展

主要市場挑戰

技術複雜性

主要市場趨勢

擴大治療目標

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：臨床試驗分析

第 4 章：1 正在進行的臨床試驗

第 4 章：2 項已完成的臨床試驗

第4章：3 項終止的臨床試驗

第4章：依開發階段細分的管道

第 4 章：5 條管道依狀態細分

第 4 章：6 個研究管道細分（依研究類型）

第4章：7 個管道細分（按地區）

第 4 章：8 項臨床試驗熱圖

第5章：顧客之聲

第6章：全球基因治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按載體類型（病毒載體、非病毒載體）
    • 依遞送方式（體內、體外）
    • 按適應症（罕見疾病、癌症、神經系統疾病、其他）
    • 按地區（北美、歐洲、亞太、南美、中東和非洲）
    • 按公司分類（2024）
  • 市場地圖
  • 依向量類型
  • 按交付方式
  • 按適應症
  • 按地區

第7章：北美基因治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第8章：歐洲基因治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章：亞太基因治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第10章：南美洲基因治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲基因治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章：市場動態

  • 驅動程式
  • 挑戰

第13章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 14 章：全球基因治療市場：SWOT 分析

第15章：資金分析

第 16 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 17 章：競爭格局

  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • F. Hoffmann-La Roche ltd.
  • bluebird bio, Inc.
  • Novartis AG
  • Uniqure NV

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 17109

Global Gene Therapy Market was valued at USD 6.54 Billion in 2024 and is expected to reach USD 11.29 Billion by 2030 with a CAGR of 9.53% during the forecast period. The gene therapy is described as the treatment of an illness by changing, replacing, or supplementing a missing or defective genetic combination that is responsible for the disease. The gene therapy has become one of the most desirable research goals in the fight against degenerative illnesses. The need for gene therapy is being driven by an increase in the number of cases of cancer and other chronic diseases all across the world. The advancements in gene therapies are projected to be approved in the upcoming years, contributing to the gene therapy market's growth during the forecast period. The gene therapies are designed to treat diseases by altering genetic information, such as inactivating malfunctioning genes or replacing a disease-causing gene with a healthy copy of gene. The gene therapy is being utilized to treat a variety of disorders and has demonstrated to be effective. This form of treatment can cure diseases such as diabetes, cancer, heart disease, and AIDS.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.54 Billion
Market Size 2030USD 11.29 Billion
CAGR 2025-20309.53%
Fastest Growing SegmentNon-viral vectors
Largest MarketNorth America

The strong pipeline of gene therapy products is anticipated to drive market growth over the forecast period. Researchers are actively working to make gene therapy more accessible in clinical settings. Numerous universities and research institutes are developing a diverse range of gene therapy products, which is expected to contribute significantly to revenue generation in the coming years. The number of clinical trials for gene therapy saw a notable increase between 2017 and 2018, following the FDA's approval of the first gene therapy. According to the American Society of Gene & Cell Therapy (ASGCT), approximately 1,986 gene therapy products, including CAR T-cell therapies and other genetically modified cell treatments, are currently in development, further accelerating market expansion.

Key Market Drivers

Advancements in Genetic Research

The increasing understanding of the genetic basis of diseases has enabled scientists to identify specific genes responsible for various disorders. This knowledge is crucial for designing targeted gene therapies that can correct or replace defective genes, addressing the root cause of diseases. Genetic research has identified specific genetic mutations or abnormalities that contribute to various diseases, such as inherited genetic disorders and certain types of cancer. This has provided gene therapists with clear therapeutic targets, allowing them to develop more precise and effective treatments. Advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have revolutionized gene therapy. These techniques enable scientists to accurately and efficiently edit or modify genes, opening up new possibilities for treating genetic disorders. Genetic research has paved the way for personalized medicine, where treatments are tailored to an individual's genetic makeup. This approach enhances the effectiveness of gene therapies by considering genetic variations that might affect treatment outcomes, leading to better patient responses and reduced adverse effects. Genetic research has facilitated the development of advanced delivery systems that help target specific tissues or cells with greater precision. This has improved the efficiency of gene therapy treatments, minimized off-target effects and enhancing therapeutic outcomes. The promising outcomes of genetic research have attracted substantial investment in the gene therapy sector. As the potential of gene therapies becomes more apparent, investors are more willing to fund research and development, driving innovation and market growth. For example, in December 2023, the U.S. FDA approved a gene therapy for sickle cell disease, marking the first-ever gene therapy based on CRISPR gene editing. Such groundbreaking advancements and product launches are expected to drive market growth over the forecast period.

Key Market Challenges

Technical Complexity

Developing effective gene therapies requires a deep understanding of genetics, molecular biology, and complex cellular processes. The technical complexity of designing therapies that accurately target and modify specific genes can lead to prolonged research and development timelines. Getting therapeutic genes into target cells poses a significant challenge. Developing efficient and safe delivery systems, such as viral vectors or nanoparticles, requires extensive optimization and testing. Technical difficulties in achieving precise and controlled delivery can affect the success of gene therapies. The interactions between modified genes and the host organism can sometimes lead to unintended consequences. Technical complexities can make it difficult to predict the outcomes of gene therapies accurately, leading to safety concerns and regulatory challenges. Regulatory agencies require a high level of safety and efficacy data for gene therapy products due to their complexity and potential risks. Navigating the regulatory pathway for gene therapies can be challenging and time-consuming, hindering market growth. Manufacturing gene therapy products in a consistent and scalable manner is challenging due to the complexity of biological processes involved. Ensuring the quality, safety, and stability of gene therapies at a commercial scale can be technically demanding and expensive.

Key Market Trends

Expanding Therapeutic Targets

Identifying new therapeutic targets means gene therapy can be applied to a wider range of medical conditions beyond traditional monogenic disorders. This diversity includes complex diseases like cancer, cardiovascular diseases, neurodegenerative disorders, and rare diseases, expanding the addressable patient population. The availability of gene therapies for multiple therapeutic targets attracts a larger patient base, driving market growth by increasing the potential customer pool and commercial opportunities. The discovery of new therapeutic targets stimulates research and development efforts by both established pharmaceutical companies and smaller biotechnology firms. This influx of investment fuels innovation and accelerates the development of gene therapies for various indications. Expanding therapeutic targets leads to a more diverse portfolio of clinical trials. This diversity enhances the clinical trial landscape, allowing researchers to explore different patient populations, endpoints, and treatment approaches, ultimately advancing the field. As gene therapies target a wider array of diseases, regulatory agencies may provide specialized pathways or guidelines for specific indications. This attention can expedite regulatory approval processes and facilitate market entry. The availability of gene therapies for more common and relatable diseases can increase public awareness and acceptance of the technology. Positive outcomes in well-known conditions can build trust and reduce skepticism. Expanding therapeutic targets can lead to collaborations between academic researchers, industry partners, and patient advocacy groups. Collaborations strengthen expertise, resources, and support networks, fostering innovation and growth. The potential for gene therapies to target various indications attracts diverse investors interested in contributing to the development of treatments for specific diseases, fostering a competitive market landscape.

Key Market Players

  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • bluebird bio, Inc.
  • Novartis AG
  • uniQure NV.

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Therapy Market, By Vector Type:

  • Viral Vector
  • Non-Viral Vector

Gene Therapy Market, By Delivery Method:

  • In-Vivo
  • Ex-Vivo

Gene Therapy Market, By Indication:

  • Rare Diseases
  • Cancer
  • Neurological Diseases
  • Others

Gene Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

Global Gene Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

4.1 Ongoing Clinical Trials

4.2 Completed Clinical Trials

4.3 Terminated Clinical Trials

4.4 Breakdown of Pipeline, By Development Phase

4.5 Breakdown of Pipeline, By Status

4.6 Breakdown of Pipeline, By Study Type

4.7 Breakdown of Pipeline, By Region

4.8 Clinical Trials Heat Map

5. Voice of Customer

6. Global Gene Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 6.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 6.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 6.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 6.2.5. By Company (2024)
  • 6.3. Market Map
  • 6.3.1 By Vector Type
  • 6.3.2 By Delivery Method
  • 6.3.3 By Indication
  • 6.3.4 By Region

7. North America Gene Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 7.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 7.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Gene Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Delivery Method
        • 7.3.1.2.3. By Indication
    • 7.3.2. Canada Gene Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Delivery Method
        • 7.3.2.2.3. By Indication
    • 7.3.3. Mexico Gene Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Delivery Method
        • 7.3.3.2.3. By Indication

8. Europe Gene Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 8.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 8.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Gene Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Delivery Method
        • 8.3.1.2.3. By Indication
    • 8.3.2. Germany Gene Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Delivery Method
        • 8.3.2.2.3. By Indication
    • 8.3.3. United Kingdom Gene Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Delivery Method
        • 8.3.3.2.3. By Indication
    • 8.3.4. Italy Gene Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Delivery Method
        • 8.3.4.2.3. By Indication
    • 8.3.5. Spain Gene Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Delivery Method
        • 8.3.5.2.3. By Indication

9. Asia-Pacific Gene Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 9.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 9.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Gene Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Delivery Method
        • 9.3.1.2.3. By Indication
    • 9.3.2. India Gene Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Delivery Method
        • 9.3.2.2.3. By Indication
    • 9.3.3. Japan Gene Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Delivery Method
        • 9.3.3.2.3. By Indication
    • 9.3.4. South Korea Gene Therapy Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Vector Type
        • 9.3.4.2.2. By Delivery Method
        • 9.3.4.2.3. By Indication
    • 9.3.5. Australia Gene Therapy Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Vector Type
        • 9.3.5.2.2. By Delivery Method
        • 9.3.5.2.3. By Indication

10. South America Gene Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 10.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 10.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Delivery Method
        • 10.3.1.2.3. By Indication
    • 10.3.2. Argentina Gene Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Delivery Method
        • 10.3.2.2.3. By Indication
    • 10.3.3. Colombia Gene Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Delivery Method
        • 10.3.3.2.3. By Indication

11. Middle East and Africa Gene Therapy Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 11.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
    • 11.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Gene Therapy Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Vector Type
        • 11.3.1.2.2. By Delivery Method
        • 11.3.1.2.3. By Indication
    • 11.3.2. Saudi Arabia Gene Therapy Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Vector Type
        • 11.3.2.2.2. By Delivery Method
        • 11.3.2.2.3. By Indication
    • 11.3.3. UAE Gene Therapy Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Vector Type
        • 11.3.3.2.2. By Delivery Method
        • 11.3.3.2.3. By Indication

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Global Gene Therapy Market: SWOT Analysis

15. Funding Analysis

16. Porter's Five Forces Analysis

  • 16.1. Competition in the Industry
  • 16.2. Potential of New Entrants
  • 16.3. Power of Suppliers
  • 16.4. Power of Customers
  • 16.5. Threat of Substitute Products

17. Competitive Landscape

  • 17.1. REGENXBIO Inc.
    • 17.1.1. Business Overview
    • 17.1.2. Company Snapshot
    • 17.1.3. Products & Services
    • 17.1.4. Financials (As Reported)
    • 17.1.5. Recent Developments
    • 17.1.6. Key Personnel Details
    • 17.1.7. SWOT Analysis
  • 17.2. Oxford Biomedica PLC.
  • 17.3. Voyager Therapeutics Inc.
  • 17.4. Human Stem Cells Institute
  • 17.5. Dimension Therapeutics, Inc.
  • 17.6. Bristol-Myers Squibb Company
  • 17.7. Sanofi
  • 17.8. F. Hoffmann-La Roche ltd.
  • 17.9. bluebird bio, Inc.
  • 17.10. Novartis AG
  • 17.11. Uniqure N.V.

16. Strategic Recommendations

17. About Us & Disclaimer